The purpose of this study is to dynamically observe the dynamic changes of serum IGF-1 after intracerebral hemorrhage, explore the impact and correlation of serum IGF-1 with the severity of the patient's condition and prognosis, and provide a reference for clinical treatment timing.
Research Objectives 1. Monitor the dynamic changes in serum IGF-1 concentration in patients with intracerebral hemorrhage at different time points (within 3 days, 14 days, 1 month, 2 months, and 4 months after onset). 2. Analyze the correlation between serum IGF-1 levels and the severity of intracerebral hemorrhage, imaging findings, and prognosis. 3. Explore the clinical value of serum IGF-1 as a biomarker for intracerebral hemorrhage repair. 4. Provide a reference for the clinical treatment timing of IGF-1-related drugs and therapies (such as rh growth hormone, rhIGF-1, etc.). Experimental Methods Screening Period: Within 3 days after onset, record the demographic data, etiology, medical history, complications, disease course, and main clinical manifestations of the subjects during the screening period. Blood sampling for laboratory tests (between 06:00-08:00 in the morning within 3 days after onset) includes: complete blood count, IGF-1, GH, IGFBP-3, LDL-C, thyroid function T4, serum cortisol, ACTH, testosterone or progesterone, serum CRP, fasting blood glucose, glycated hemoglobin. Perform head CT and NIHSS scoring. Follow-up Period: At the 15th day, 1st month, and 2nd month of the subject's disease course: Conduct laboratory tests for IGF-1, GH, and IGFBP-3. Evaluate using the Modified Barthel Index (MBI), Modified Rankin Scale (MRS), Glasgow Coma Scale (GCS), Mini-Mental State Examination (MMSE), PHQ-9 Depression Screening Scale (PHQ-9), and World Health Organization Quality of Life-BREF (WHOQOL-BREF). At the 4th month of the subject's disease course: Perform laboratory tests for complete blood count, IGF-1, GH, IGFBP-3, LDL-C, thyroid function T4, serum cortisol, ACTH, testosterone or progesterone, CRP, fasting blood glucose, and glycated hemoglobin. Evaluate using the same scales as above (MBI, MRS, GCS, MMSE, PHQ-9, WHOQOL-BREF). Grouping Based on Dynamic Changes in Serum IGF-1: Convert IGF-1 values to IGF-1 SD (standard deviation) by referencing the age-specific reference values for IGF-1 in healthy Chinese populations (Peking Union Medical College). IGF-1 Decreased Group: IGF-1 \< 0SD IGF-1 Normal Group: 0SD ≤ IGF-1 ≤ 2SD Dynamic change-based grouping: ① Persistent IGF-1 Decrease Group: IGF-1 remains \< 0SD throughout dynamic observation. ② IGF-1 Decrease to Normal Group: IGF-1 first \< 0SD, then recovers to \> 0SD. ③ Persistent IGF-1 Normal Group: IGF-1 remains \> 0SD throughout dynamic observation. Statistical Analysis Based on Experimental Data
Study Type
OBSERVATIONAL
Enrollment
100
The relationship between serum IGF-1 levels within 3 days after intracerebral hemorrhage and the severity of the condition (referring to NIHSS score)
Serum IGF-1 levels decrease in the acute phase after intracerebral hemorrhage, and the decrease is correlated with the severity of the condition. (The more severe the condition, the larger the number of patients with reduced IGF-1 levels, and the more significant the decrease in IGF-1 values.)，The higher the IGF-1 level, the lower the NIHSS score.
Time frame: 3 days after intracerebral
The correlation between the dynamic change trend of IGF-1 after intracerebral hemorrhage and the prognosis of patients
Patients with persistently decreasing IGF-1 levels have worse functional prognosis than those with persistently normal IGF-1 levels.
Time frame: The 5th month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.